Hisun Cooperates With MNCs To Tap International Market
This article was originally published in PharmAsia News
Executive Summary
After getting Eli Lilly's technology transfer on processing capreomycin raw material, Zhejiang Hisun Pharmaceutical is building a production line capable of producing 3 million to 5 million doses of capreomycin annually. The company will complete its registration and Good Manufacturing Practices authentication in China this year. It is also preparing documentation for World Health Organization registration and approval, and may be WHO's only supplier of capreomycin in China. Its doses will be ready for the international market in two years. Hisun has a joint venture with Xinghai Pharmaceutical and Spain Farmaprojects S. A. that taps on the latter's overseas sales channels. Besides the capreomycin collaboration, Lilly may consider acquiring Hisun's products still in development as well as use the Chinese firm to manufacture its drugs. (Click here for more - Chinese Language)